Xenon Pharmaceuticals Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2014. Amounts are in U.S. dollars; financial statement amounts below are in millions unless noted. Xenon is a clinical-stage biopharmaceutical company whose revenue primarily comes from collaboration agreements, not product sales.
Financial performance and liquidity
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $13.19 | $10.79 | $23.49 | $21.77 |
| Operating expenses | $4.53 | $4.27 | $12.42 | $14.08 |
| Operating income | $8.66 | $6.52 | $11.07 | $7.69 |
| Net income | $9.19 | $6.38 | $11.79 | $9.52 |
| Operating margin | 65.6% | 60.4% | 47.1% | 35.3% |
Operating margins are calculated from reported revenue and operating income. Quarterly revenue growth was primarily driven by an $8.0 million Genentech milestone in August 2014, offset in the comparison by a $5.1 million Genentech milestone recognized in Q3 2013. Nine-month revenue also included the new Genentech pain-genetics collaboration. These milestone-related results are not a reliable indicator of recurring revenue.
- Cash and liquidity: Cash and cash equivalents were $33.73 million and marketable securities $14.21 million at September 30, for combined liquidity of $47.94 million, versus $49.28 million at December 31, 2013. Current assets were $48.27 million and current liabilities $16.34 million.
- Cash flows: Operating activities provided $3.22 million in the first nine months of 2014, compared with $0.64 million used in the same 2013 period. Investing activities used $4.28 million and financing activities used $1.30 million. Cash and cash equivalents declined $4.22 million during the period.
- Debt and balance sheet: The company reported no outstanding debt at September 30, 2014. Total liabilities were $19.17 million, including deferred revenue. Accumulated deficit was $104.96 million; shareholders’ deficit was $67.51 million.
- R&D and G&A: Nine-month R&D expense fell to $8.32 million from $9.56 million, mainly because Xenon discontinued XEN701 in late 2013. Q3 R&D rose to $3.22 million from $2.58 million. Nine-month G&A declined to $4.11 million from $4.52 million.
Material developments and outlook
- In September 2014, Genentech initiated a Phase 1 trial of GDC-0276; its $8.0 million Health Canada clinical-trial-application milestone was recognized in Q3. A separate Genentech pain-genetics agreement signed in March 2014 provided a $1.5 million upfront payment, recognized over two years, and potential additional milestones.
- Other pipeline updates: Teva was conducting a 300-patient Phase 2b trial of TV-45070 in knee osteoarthritis and expected to start a Phase 2b postherpetic-neuralgia trial in the first half of 2015. Xenon anticipated an IND filing for XEN801 in the first half of 2015 and for its Dravet syndrome program in 2016. These are management expectations, not guarantees.
- Management expected significant expenses and operating losses for the foreseeable future, despite reported 2014 interim net income. It estimated available cash, marketable securities, subsequent offering proceeds and expected collaboration research funding would support operating and capital needs for at least 12–24 months. Management cautioned that assumptions could prove wrong and that this funding would not be sufficient to complete clinical development and prepare for commercialization of any candidate.
- Subsequent financing: On October 1, 2014, Xenon effected a 1-for-4.86 reverse share split; reported share data were retrospectively adjusted. On November 10, it completed an IPO of 4.6 million shares at $9.00 per share and a concurrent Genentech-affiliate placement of 495,000 shares at $9.00. The IPO generated approximately $34.1 million net of all stated expenses; the company separately reported approximately $4.1 million from the placement, net of underwriting fees but before offering expenses. These proceeds were not included in September 30 cash balances. After the transactions, 14,181,333 common shares were outstanding.
- Key risks include reliance on collaborators and milestone payments, clinical and regulatory uncertainty, no product-sales royalties to date, possible need for additional financing, foreign-exchange exposure, and the challenge of commercializing orphan-disease products. A 10% move in the U.S. dollar was estimated to change reported earnings by about $0.6 million on U.S.-dollar cash balances. Xenon disclosed no material legal proceedings; potential contractual indemnification obligations were unquantified, but management considered their fair value minimal. Disclosure controls were assessed as effective, with no material quarterly change in internal control over financial reporting.
Most important facts for investors to verify
- Whether collaboration revenue and milestone receipts continue, and how much reported earnings depend on one-time milestones versus ongoing research funding.
- Actual cash burn and runway after the IPO and placement, including the timing and amount of future R&D spending and any additional financing needs.
- Progress and outcomes for GDC-0276, TV-45070, XEN801 and the Dravet syndrome program against the stated development expectations.
- Offering proceeds, share-count changes, option dilution and the post-IPO capitalization; distinguish the September 30 balance sheet from subsequent financing.
- Foreign-exchange effects and any changes in collaboration terms, partner priorities, clinical timelines or regulatory requirements.